AMENDMENTS TO THE SPECIFICATION:

Ţ

On page 8, before paragraph [040], please insert the following paragraph:

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 is a histogram representing the effect of magnesium gluconate (10⁻⁴ M) or of 1% Argireline® on calcium channels and the effect of their combination on type-L calcium channels, verapamil site, obtained from the results of Example 1 as disclosed herein.

On pages 24-27, please amend paragraph [0108] as shown below:

The following compositions were prepared in a conventional manner for those skilled in the art. The amounts indicated are percentages by weight.

COMPOSITION 1: O/W EMULSION

Phase A	Water	qs 100%
	Preserving agents	0.35%
	Manganese gluconate	0.05%
Phase B1	Silicone oils	3%
	Cetyl alcohol and stearyl alcohol	1.6%
	Hydrogenated polyisobutene	4%
	Polyethylene glycol (100 EO)	2%
Phase B2	Volatile silicone oils	3%
Phase D	Crosslinked polyacrylamido	1%

Attorney Docket No. 05725.1275-00000

1%

Application No.: 10/705,857

methylpropanesulphonic acid (Hostacerin AMPS from Clariant)

Phase E

Acetyl glutamyl-glutamyl-methionyl-glutaminyl-arginyl-arginylamide

(SEQ ID No. 2) hexapeptide at 0.05% in water

(Argireline from Lipotec)

COMPOSITION 2: W/O EMULSION

Phase A	Water	qs 100%
	Citric acid	0.05%
	Preserving agents	0.95%
	50% sodium hydroxide	2.98%
	Vinylpyrrolidone/styrene copolymer as a 40% emulsion	3.34%
	Fucose-rich polysaccharide at 1% in water (Fucogel from Solabia)	2%
	Oxyethylenated (20 EO) sorbitan monolaurate	1%
	Sodium citrate	1.6%
	Magnesium gluconate	0.05%
	Acetyl glutamyl-glutamyl-methionyl-glutaminyl-arginyl-arginylamide (SEQ ID No. 2) hexapeptide at 0.05% in water (Argireline from Lipotec)	1%
Phase B	Oxyethylenated (18 EO) oxypropylenated (18 PO) mixture of cyclopentasiloxane and polydimethylsiloxane	10%
	Cyclopentasiloxane	8%

Attorney Docket No. 05725.1275-00000 Application No.: 10/705,857

		Siloxane elastomer at 20% in polydimethylsiloxane (KSG-1 from Shin-Etsu)	3%	
Phase C		Acrylamide/sodium acrylamido- 2-methylpropanesulphonate copolymer as a 40% inverse emulsion (Sepigel 305 from SEPPIC)	2%	
COM	POSIT	ION 3: GEL		
Glycerol		rol	4%	
	Propy	vlene glycol	3%	
	Prese	erving agents	qs	
	2-met	amide/sodium acrylamido- thylpropanesulphonate copolymer 40% inverse emulsion gel 305 from SEPPIC)	1.5%	
	Metha	acrylate copolymer powder	1%	
	Alveri	ne	0.1%	
	glutar (SEQ	l glutamyl-glutamyl-methionyl- ninyl-arginyl-arginylamide <u>ID No. 2)</u> hexapeptide at 0.05% in water eline from Lipotec)	4%	
	Wate	r	qs 100%	
COMPOSITION 4: SERUM				
	Sodiu	m hydroxide	0.1%	
	Tocop	oheryl acetate	0.5%	
	Disod	ium salt of EDTA	0.1%	
	Hydro	ogenated polyisobutene	4.0%	
	Caffe	ine	0.2%	

7

Attorney Docket No. 05725.1275-00000 Application No.: 10/705,857

Magnesium gluconate	0.5%
Glycerol	3.0%
Preserving agents	1.2%
Cyclohexadimethylsiloxane	6.0%
Crosslinked polyacrylamidomethyl-	1.0%
propanesulphonic acid (Hostacerin AMPS	
from Clariant)	
Yeast extract	0.3%
Acetyl glutamyl-glutamyl-methionyl- glutaminyl-arginyl-arginylamide (SEQ ID No. 2) hexapeptide at 0.05% in water (Argireline from Lipotec)	1.0%
Citric acid	0.1%
Tensioning agents	7.0%
Water	qs 100%